Thought Leadership
At NDA our experts stay abreast with the evolving environment and the new regulatory requirements that it gives rise to. One of the results of these activities is a stream of articles, commentaries and white papers that we publish for the benefit of our clients and followers. It captures the state of the art of our industry today.
We call it Thought Leadership.
Articles and White Papers
Service:
Scientific:
Sort by:
All services
Development Strategy
Medical Devices
Pharmacovigilance
NDA Advisory Board
Strategic Communications
Regulatory
Quality & Compliance
All expertise
Oncology
Vaccine
Immunogenicity
HTA
In-Vitro Diagnostics
Non-Clinical
Cell and Gene Therapy
Biostatistics
Cardiology
ATMP
Rare Disease
Market Access
CMC
Clinical
Paediatric
Acceleration Strategies
Medical Devices
Quality
Patient Safety
29-11-2021
Oral explanation – Your product’s last stand
In this article, we provide insight into oral explanations and what you need to emphasize in a presentation in order to engage with EU regulators.
20-10-2021
Controlled Human Infection Studies
NDA's Dr Paula Salmikangas and Dr Pieter Neels co-wrote and shared their knowledge in this insightful article that was published on the 4th of October in Biologicals.
13-10-2021
A new dawn in Regulation and Access
Scientific Writer, Ingela Loell, provides insight into ILAP and the collaborations providing quicker approval and patient access.
06-10-2021
NDA Webinar: Optimise your interactions with European Regulatory Agencies
In this webinar Dr Roz Cox discusses the opportunities for interacting with European Regulatory Agencies, and how to optimise these interactions
01-09-2021
Vaccine platform technologies – Learnings from the COVID-19 pandemic
NDA Advisory Board Members, Steffen Thirstrup and Pieter Neels provide an insight into current vaccine platform technology and how the rapid response to tackle emerging infectious diseases can be further improved.
04-06-2021
Patient Access in the real world: Addressing challenges and opportunities.
NDA Advisory Board Members, Mel Walker and Yngve Mikkelsen provide an insight into how global events can impact patient access in a real-world setting.